Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
P/B ratio for Apogee Therapeutics, Inc. (APGE)
P/B ratio as of 2023: 3.73
According to Apogee Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.73. At the end of 2022 the company had a P/B ratio of -27.04.
P/B ratio history for Apogee Therapeutics, Inc. from 2022 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.73 |
| 2022 | -27.04 |